Macrocin, relomycin and tylosin are structurally related macrolide antibiotics produced by Streptomyces fradiae1,2,3) In addition to these three substances, desmycosin4), a compound similar to tylosin but lacking mycarose, has also been described. The structures of these antibiotics are presented as Fig. 1 . All four of the compounds have recently been shown to be interrelated in a biosynthetic pathway". Since macrolide antibiotics are known to inhibit bacterial protein synthesis by binding to ribosomes5), a study was undertaken to determine if there is a correlation between the ability of these four natural products to bind to ribosomes and to inhibit bacterial growth.
Similar studies using other antibiotics and their semi-synthetic derivatives have been reported6,7,8).
To test the effect of the antibiotics on the growth of Bacillus subtilis 168, 100 ml of trypticase-soy broth was inoculated from a slant culture and incubated 18 hours at 37°C on a shaker (2.54 cm throw, 250 rpm). When the ability of the antibiotics to inhibit the growth of Bacillus subtilis 168 was coinpared, macrocin and tylosin were found to have similar activity (Fig. 2) . The least active compound tested was observed to be desmycosin, while relomycin was found to have intermediate activity.
In contrast, when the same antibiotics were examined for their ability to bind to ribosomes, desmycosin appeared to be the most active (Fig. 3) . In this test, little difference was observed in the binding properties of macrocin, relomycin and tylosin. One may assume that the overall potency of a macrolide antibiotic is related to two major properties; one its ability to effectively interact with the ribosomal target and the other its ability to reach that target in sufficiently high concentration. It follows that if a series of compounds are of similar potency in both the cell-free ribosomal binding assay and the whole cell growth inhibition assay the structure-activity relationships among the antibiotics do not differ significantly with respect to either barrier. On the other hand, any major difference between the cell-free and whole cell assays reflect a change either in the accumulation of the antibiotic at the target site or in its ability to react at the target. Previous studies with some derivatives of erythromycin A have indicated that there is little difference among them with respect to some. An explanation similar to this has been offered for the erythromycin family of antibiotic8).
In that series, the basic monoglycoside desosaminyl-erythronolide B which lacks a neutral sugar is active in cell-free assays using B. subtilis but is not effective against the whole bacteria. . Biochem. 6: 2578 . Biochem. 6: -2585 . Biochem. 6: , 1967 
